Jump to navigation Jump to search
Clinical data
SynonymsBMY 45594
BMS 182751
(OC-6-43)-bis(acetato)amminedichlorocyclohexylamine platinum(IV)
Routes of
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass500.277 g/mol

WikiDoc Resources for Satraplatin


Most recent articles on Satraplatin

Most cited articles on Satraplatin

Review articles on Satraplatin

Articles on Satraplatin in N Eng J Med, Lancet, BMJ


Powerpoint slides on Satraplatin

Images of Satraplatin

Photos of Satraplatin

Podcasts & MP3s on Satraplatin

Videos on Satraplatin

Evidence Based Medicine

Cochrane Collaboration on Satraplatin

Bandolier on Satraplatin

TRIP on Satraplatin

Clinical Trials

Ongoing Trials on Satraplatin at Clinical

Trial results on Satraplatin

Clinical Trials on Satraplatin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Satraplatin

NICE Guidance on Satraplatin


FDA on Satraplatin

CDC on Satraplatin


Books on Satraplatin


Satraplatin in the news

Be alerted to news on Satraplatin

News trends on Satraplatin


Blogs on Satraplatin


Definitions of Satraplatin

Patient Resources / Community

Patient resources on Satraplatin

Discussion groups on Satraplatin

Patient Handouts on Satraplatin

Directions to Hospitals Treating Satraplatin

Risk calculators and risk factors for Satraplatin

Healthcare Provider Resources

Symptoms of Satraplatin

Causes & Risk Factors for Satraplatin

Diagnostic studies for Satraplatin

Treatment of Satraplatin

Continuing Medical Education (CME)

CME Programs on Satraplatin


Satraplatin en Espanol

Satraplatin en Francais


Satraplatin in the Marketplace

Patents on Satraplatin

Experimental / Informatics

List of terms related to Satraplatin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Satraplatin (INN, codenamed JM216) is a platinum-based antineoplastic agent that is under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration.[1] First mentioned in the medical literature in 1993,[2] satraplatin is the first orally active platinum-based chemotherapeutic drug;[3] other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.

It is made available in the United States jointly by Spectrum Pharmaceuticals and GPC Biotech under the name SPERA (SatraPlatin Expanded Rapid Access).

The drug has also been used in the treatment of lung and ovarian cancers. The proposed mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing.[4]


  1. Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials". Dalton Transactions. 39 (35): 8113–27. doi:10.1039/C0DT00292E. PMID 20593091.
  2. Kelland LR, Abel G, McKeage MJ; et al. (1993). "Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug" (PDF). Cancer Res. 53 (11): 2581–6. PMID 8388318.
  3. Choy H, Park C, Yao M (2008). "Current status and future prospects for satraplatin, an oral platinum analogue". Clin Cancer Res. 14 (6): 1633–8. doi:10.1158/1078-0432.CCR-07-2176. PMID 18347164.
  4. Satraplatin — Spectrum Pharmaceuticals